<DOC>
	<DOCNO>NCT02313012</DOCNO>
	<brief_summary>The CC-90003-ST -001 trial first-in-man , open-label study subject locally-advanced wide spread cancer determine CC-90003 ( oral medication ) adequately tolerate minimal side effect .</brief_summary>
	<brief_title>Safety PK Study CC-90003 Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description>CC-90003-ST -001 open-label , multicenter , Phase 1a study subject locally-advanced metastatic , solid tumor intolerant , resistant , relapse least one line therapy standard therapy exist . The study conduct two part : Dose Escalation ( Part 1 ) Cohort Expansion ( Part 2 ) . Subjects may continue CC-90003 progression underlie malignancy , occurrence intolerable toxicity , physician/subject decision discontinue CC-90003 . In Part 1 , cohort subject relapse refractory solid tumor receive increase dos CC-90003 order ass safety tolerability , maximum tolerate dose ( MTD ) , PK profile . In Part 2 , cohort subject specific tumor harbor mutation involve Mitogen -Activated Protein Kinase ( MAPK ) pathway receive CC-90003 MTD progression disease , intolerable toxicity , physician/subject decision discontinue CC-90003 .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Eligible study subject Part 1 Part 2 must 18 year old 2 . Eligible study subject must histologic cytologic confirmation advance , unresectable metastatic solid tumor , least one measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 3 . Eligible study subject must Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 4 . Eligible study subject must exhibit acceptable liver , bone marrow , renal cardiac function assess laboratory test , ECG ECHO MUGA scan . 1 . Subjects symptomatic unstable CNS metastases 2 . Subjects history recent ( within 28 day ) systemic therapy underlying malignancy 3 . Subjects surgery/radiotherapy within 2 week prior start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Locally Advanced Tumors</keyword>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>Relapsed refractory , BRAFV600 RAS-mutated solid tumor</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Colorectal Carcinomas Papillary</keyword>
	<keyword>Thyroid carcinoma</keyword>
	<keyword>Pancreatic ductal Adenocarcinomas</keyword>
	<keyword>Non -small cell lung cancer [ NSCLC ]</keyword>
</DOC>